BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics

BioCryst Pharmaceuticals, Inc. (BCRX)

Today's Latest Price: $3.64 USD

0.07 (-1.89%)

Updated Oct 28 10:50am

Add BCRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

BCRX Stock Summary

  • With a price/sales ratio of 13.78, Biocryst Pharmaceuticals Inc has a higher such ratio than 89.29% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 8 for Biocryst Pharmaceuticals Inc; that's greater than it is for 86.89% of US stocks.
  • As for revenue growth, note that BCRX's revenue has grown 327.11% over the past 12 months; that beats the revenue growth of 97.94% of US companies in our set.
  • Stocks that are quantitatively similar to BCRX, based on their financial statements, market capitalization, and price volatility, are ALBO, FOLD, STRO, CLSN, and EIDX.
  • BCRX's SEC filings can be seen here. And to visit Biocryst Pharmaceuticals Inc's official web site, go to

BCRX Stock Price Chart Interactive Chart >

Price chart for BCRX

BCRX Price/Volume Stats

Current price $3.64 52-week high $6.29
Prev. close $3.71 52-week low $1.38
Day low $3.58 Volume 1,401,173
Day high $3.70 Avg. volume 7,300,669
50-day MA $3.81 Dividend yield N/A
200-day MA $3.71 Market Cap 642.70M

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio

Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.

BCRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BCRX Latest Social Stream

Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

BioCryst Pharmaceuticals started at Overweight at JPMorgan

JPMorgan initiates BioCryst Pharmaceuticals ([[BCRX]] +2.9%) with an Overweight rating and $7 price target (indicating 86.2% upside from current levels).Analyst Jessica Fye sees BioCryst's "soon-to-be-approved" Orladeyo for hereditary angioedema prophylaxis as an underappreciated value driver.Orladeyo PDUFA (approval in U.S.) is expected on Dec. 3, 2020, while approval decision on Orladeyo JNDA from...

Seeking Alpha | September 29, 2020

BioCryst Pharmaceuticals, Inc. (BCRX) Investor Presentation - Slideshow

The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 15, 2020

BioCryst to Report Second Quarter 2020 Financial Results on August 6

RESEARCH TRIANGLE PARK, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID 5142479. A live webcast of the call and any slides will be available online at the investors section of the company website at A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international calle...

Yahoo | July 23, 2020

Did Hedge Funds Make The Right Call On BioCryst Pharmaceuticals, Inc. (BCRX) ?

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 18, 2020

Better Buy: Moderna vs. BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (NASDAQ: BCRX) and Moderna (NASDAQ: MRNA) are both biotech companies developing products to combat the COVID-19 pandemic, but the similarities end there. Moderna is a leading company in the race for a COVID-19 vaccine, making it one of the most rapidly growing biotech stocks as well as one of the most-watched companies in the industry. The company's market cap has more than quadrupled over the past 12 months, growing from $4.8 billion in June 2019 to more than $24 billion today.

Yahoo | July 15, 2020

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo -0.82%
3-mo -13.74%
6-mo 2.82%
1-year 58.26%
3-year -17.65%
5-year -59.51%
YTD 5.51%
2019 -57.25%
2018 64.36%
2017 -22.43%
2016 -38.66%
2015 -15.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7758 seconds.